Core Viewpoint - The stock of Haisco Pharmaceutical Group Co., Ltd. has experienced fluctuations, with a year-to-date increase of 53.27% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Haisco achieved a revenue of 2 billion yuan, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million yuan [2]. - Cumulatively, Haisco has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of Haisco's shareholders increased by 25.93% to 11,400, while the average circulating shares per person decreased by 28.64% to 42,147 shares [2]. - The top ten circulating shareholders include several funds, with notable increases in holdings from China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3]. Stock Market Activity - On October 13, Haisco's stock price fell by 2.05% to 50.55 yuan per share, with a trading volume of approximately 54.66 million yuan and a turnover rate of 0.22% [1]. - The stock's market capitalization stands at 56.612 billion yuan, with a net inflow of main funds amounting to 2.05 million yuan [1].
海思科跌2.05%,成交额5466.47万元,主力资金净流入205.01万元